ReviewInternational journal of molecular medicine2026
Role of extracellular matrix in liver fibrosis regression and regeneration (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extracellular matrix (ECM), a critical component of the cellular microenvironment, is intimately linked to normal physiological functions and pathological alterations in tissues. In the liver, ECM homeostasis governs key processes including fibrogenesis, fibrosis regression and regeneration. These processes are not only influenced by ECM dynamics but also interconnected through ECM remodeling. These processes are closely related to Hepatic stellate cells and matrix metalloproteinases to a large extent. They are influenced by various pathways such as transforming growth factor‑β, hepatocyte growth factor, integrin‑linked kinase, Yes‑associated protein, regulating their activation, cellular senescence and functional processes. Elucidating the mechanisms regulating ECM alterations holds significant implications for developing therapies targeting liver fibrosis regression and regenerative enhancement. Currently, multiple drugs under research have been shown to affect the progression of liver fibrosis through these related mechanisms. Furthermore, such insights may contribute substantially to preventing malignant lesions, including hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.